Glyn Edwards, Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) chief executive, has highlighted the group’s progress through its ongoing clinical programmes.
Edwards, in the Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI) drug developer’s quarterly results statement, told investors that a landmark DMD programme had continued to gain momentum.
“We initiated our Phase 2 proof of concept clinical trial, PhaseOut DMD, of ezutromid and are actively enrolling patients in the UK.
“This trial represents the first long-term clinical trial of a utrophin modulator, a potential disease-modifying therapy applicable to all patients with DMD. We look forward to receiving data from the first group of 24-week biopsies in Q2/Q3 2017.”
He also highlighted positive findings of a separate Phase 1 trial. The trial results showed that a new formulation had achieved over a six-fold increase in maximum plasma levels but with a reduced oral dose compared to the current formulation.
“With these results, we plan to incorporate the new formulation, subject to regulatory approval, into PhaseOut DMD alongside the current formulation. Including both formulations allows us to further explore the potential therapeutic effect of ezutromid with an expanded range of blood concentrations,” Edwards said.
Separately, Edwards noted the progress with the company’s Phase 2 CDI trial and highlighted that the company continues to evaluate its options to advance into Phase 3.
He added: “In our CDI programme, additional results from our Phase 2 CoDIFy clinical trial support ridinilazole as a highly selective, microbiome-sparing antibiotic that has great promise in both the treatment of the initial infection and in reducing CDI recurrences, the key issue in the treatment of CDI.”
Summit finished the second quarter with £7mln of cash and equivalents. The pre-revenue drug developer reported an £11.5mln loss for the six months ended July 31.